National cancer registries in Asia – is Big Data the way to go?
Integrated, comprehensive databases may help to close the gap in cancer care between high- and low-/lower-middle-income countries
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Enhanced patient participation in trials may help make cancer research more heterogeneous
In the Patient Advocacy Track, the importance and challenges around placing the patient at the centre of clinical trials
What level of evidence do we need for drug approval in rare cancers?
Achieving clarity in levels of clinical evidence required by regulatory bodies is still a major obstacle to expediting research in the field, says Prof. Paolo G. Casali from the Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, and the University of Milan, Italy
Some practice-changing results in breast cancer are perceived differently in low-resourced countries
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
Do biosimilars improve access to oncology medicines in Asia?
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Healthcare budgets are still a main hurdle to global use of molecular testing for precision oncology
Inequities in access to targeted cancer treatments are due to the high costs of tests, limited number of approved medicines or clinical trials and poor communication with patients, as two new surveys report